Cargando…

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States

A comprehensive description of the contemporary trends in pulmonary arterial hypertension (PAH) related hospitalizations, associated inpatient outcomes and predictors of worse outcomes were reported in our paper recently published in the International Journal of Cardiology [1]. Our observational ana...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaturvedi, Abhishek, Kanwar, Manreet, Chandrika, Parul, Thenappan, Thenappan, Raina, Amresh, Benza, Raymond L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Data Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502330/ https://www.ncbi.nlm.nih.gov/pubmed/32995395 http://dx.doi.org/10.1016/j.dib.2020.106303

Ejemplares similares

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension
por: Benza, Raymond L., et al.
Publicado: (2021)

Pulmonary Arterial Hypertension and Sex in the Right Ventricle: It Is an Interesting Picture!
por: Thenappan, Thenappan, et al.
Publicado: (2020)

Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps
por: Kanwar, Manreet K., et al.
Publicado: (2021)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Late-onset pulmonary arterial hypertension in repaired D-transposition of great arteries: an uncommon complication
por: Baskaran, Janani, et al.
Publicado: (2017)

Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2020)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

Pulmonary hypertension in chronic kidney disease: a hemodynamic characterization
por: Thenappan, Thenappan
Publicado: (2017)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Thenappan, Thenappan, et al.
Publicado: (2021)

With No Lysine Kinase 1 Promotes Metabolic Derangements and RV Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2021)

Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again
por: Prins, Kurt W., et al.
Publicado: (2018)

Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension
por: Joshi, Aditya A., et al.
Publicado: (2018)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Colchicine Depolymerizes Microtubules, Increases Junctophilin‐2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension
por: Prins, Kurt W., et al.
Publicado: (2017)

Intermittent Fasting Enhances Right Ventricular Function in Preclinical Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2021)

Sex differences in right ventricular function between Groups 1 and 3 pulmonary hypertension
por: Kazmirczak, Felipe, et al.
Publicado: (2023)

Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry
por: Fakhri, Shoaib, et al.
Publicado: (2020)

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
por: Chang, Kevin Y., et al.
Publicado: (2022)

Effect of Chronic Digoxin Use on Mortality and Heart Failure Hospitalization in Pulmonary Arterial Hypertension
por: Chang, Kevin Y., et al.
Publicado: (2023)

Risk assessment in pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2016)

Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis
por: Kalra, Rajat, et al.
Publicado: (2020)

Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension
por: Prins, Kurt W., et al.
Publicado: (2020)

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
por: Benza, Raymond L., et al.
Publicado: (2017)

Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis
por: Prins, Kurt W., et al.
Publicado: (2017)

The WHO classification of pulmonary hypertension: A case-based imaging compendium
por: Ryan, John J., et al.
Publicado: (2012)

Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes
por: Burger, Charles D, et al.
Publicado: (2017)

The Evolution of Risk Assessment in Pulmonary Arterial Hypertension
por: Murthy, Sandhya, et al.
Publicado: (2021)

Pulmonary tumor thrombotic microangiopathy: Exploration into current diagnostic aids and therapeutics
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Clinical Determinants and Prognostic Implications of Right Ventricular Dysfunction in Pulmonary Hypertension Caused by Chronic Lung Disease
por: Prins, Kurt W., et al.
Publicado: (2019)

Excess Protein O-GlcNAcylation Links Metabolic Derangements to Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2020)

The economic burden of pulmonary arterial hypertension in Spain
por: Zozaya, Néboa, et al.
Publicado: (2022)

Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
por: Thenappan, Thenappan, et al.
Publicado: (2020)

Hemodynamic Characteristics and Outcomes of Pulmonary Hypertension in Patients Undergoing Tricuspid Valve Repair or Replacement
por: Vijayaraghavan, Mahima, et al.
Publicado: (2020)

Incidence and Risk Factors of Pulmonary Hypertension After Venous Thromboembolism: An Analysis of a Large Health Care Database
por: Lutsey, Pamela L., et al.
Publicado: (2022)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR)
por: Minhas, Jasleen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ivi2271b4ksjtc586n4f6pa1hh